4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 6.2% – Time to Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares dropped 6.2% during trading on Monday . The stock traded as low as $13.75 and last traded at $13.76. 551,066 shares were traded during mid-day trading, a decline of 34% from the average session volume of 830,914 shares. The stock had previously closed at $14.67.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.62.

4D Molecular Therapeutics Stock Up 1.7%

The company has a market cap of $792.69 million, a PE ratio of -5.46 and a beta of 2.74. The firm has a 50-day simple moving average of $12.34 and a two-hundred day simple moving average of $10.41. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Insider Activity at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This represents a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 198,574 shares of company stock worth $2,220,985 in the last three months. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new stake in 4D Molecular Therapeutics in the 1st quarter valued at about $46,000. Millennium Management LLC lifted its holdings in shares of 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter worth approximately $39,000. American Century Companies Inc. boosted its position in shares of 4D Molecular Therapeutics by 11.5% in the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after acquiring an additional 5,026 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in 4D Molecular Therapeutics by 11.7% in the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after purchasing an additional 2,284 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.